We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DN:CRYPTOCAPMarket Cap DN, $ Analysis

Data as of 2026-06-19 - not real-time

$3.35

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Denison Mines (DN) is trading at $3.35, comfortably above the $2.80 support level and below the $3.68 resistance, with a neutral RSI of 51 and a bullish MACD histogram (+0.03) indicating short‑term upside potential. The 20‑day SMA (3.26) sits just above the 200‑day SMA (3.24) while still lagging the 50‑day SMA (3.52), suggesting the stock is at a technical inflection point. Volume is increasing and volatility is high at 65% over the past 30 days, which amplifies both upside and downside moves. Fundamentally, the company carries a high debt‑to‑equity ratio (~280%) and negative cash flows, yet analysts rate it a "strong buy" with a target price of $4.83, implying a 44% upside.
The uranium sector’s regulatory environment adds a layer of risk, but the Canadian operating base limits geographic exposure. With no dividend and a price‑to‑book of 16.3, the valuation appears stretched, but the market’s extreme greed sentiment (91.46) and the sizable upside potential may justify a speculative play for investors comfortable with high beta (≈2) and sector volatility.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD crossover with positive histogram
  • Price holding above strong $2.80 support
  • Rising volume indicating market participation

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst consensus of strong‑buy and $4.83 target price
  • Uranium demand tailwinds supporting project development
  • Substantial cash on hand (~$560M) offsetting current debt load

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High debt‑to‑equity and negative cash flows constrain profitability
  • Regulatory and commodity price volatility in the uranium sector
  • Potential upside limited by overvalued price‑to‑book and price‑to‑sales ratios

Key Metrics & Analysis

Financial Health

Revenue Growth-19.60%
P/E Ratio-82.6
ROE-73.79%
ROA-5.99%
Debt/Equity280.62
P/B Ratio16.3
Op. Cash Flow$-86779000
Free Cash Flow$-95892000
Industry P/E20.1

Technical Analysis

TrendNeutral
RSI51.1
Support$2.80
Resistance$3.68
MA 20$3.26
MA 50$3.52
MA 200$3.24
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46

Valuation

Target Price$4.83
Upside/Downside44.12%
GradeUndervalued
TypeBlend

Risk Assessment

Beta2.03
Volatility65.04%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.